Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, MI, USA.
Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Nat Rev Endocrinol. 2022 Nov;18(11):665-682. doi: 10.1038/s41574-022-00730-2. Epub 2022 Aug 31.
Primary aldosteronism is a common cause of hypertension and is a risk factor for cardiovascular and renal morbidity and mortality, via mechanisms mediated by both hypertension and direct insults to target organs. Despite its high prevalence and associated complications, primary aldosteronism remains largely under-recognized, with less than 2% of people in at-risk populations ever tested. Fundamental progress made over the past decade has transformed our understanding of the pathogenesis of primary aldosteronism and of its clinical phenotypes. The dichotomous paradigm of primary aldosteronism diagnosis and subtyping is being redefined into a multidimensional spectrum of disease, which spans subclinical stages to florid primary aldosteronism, and from single-focal or multifocal to diffuse aldosterone-producing areas, which can affect one or both adrenal glands. This Review discusses how redefining the primary aldosteronism syndrome as a multidimensional spectrum will affect the approach to the diagnosis and subtyping of primary aldosteronism.
原醛症是高血压的常见病因,通过高血压和直接损害靶器官的机制,成为心血管和肾脏发病率和死亡率的危险因素。尽管原醛症患病率高且相关并发症多,但仍未得到充分认识,高危人群中接受检查的人数不足 2%。过去十年取得的重大进展改变了我们对原醛症发病机制及其临床表型的认识。原醛症的诊断和亚型划分的二分法模式正在被重新定义为疾病的多维谱,涵盖亚临床阶段到明显的原醛症,从单灶或多灶到弥漫性醛固酮产生区,可影响一个或两个肾上腺。本文讨论了将原醛症综合征重新定义为多维谱将如何影响原醛症的诊断和亚型划分方法。